IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines

The recent RESORCE trial showed that treatment with Regorafenib after Sorafenib failure provided a significant improvement in overall survival in HCC patients. Preclinical and clinical trial data showed that Regorafenib is a more potent drug than Sorafenib. In this study we aimed at improving Regora...

Descripción completa

Detalles Bibliográficos
Autores principales: Refolo, Maria Grazia, D’Alessandro, Rosalba, Lippolis, Catia, Carella, Nicola, Cavallini, Aldo, Messa, Caterina, Carr, Brian Irving
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732742/
https://www.ncbi.nlm.nih.gov/pubmed/29262576
http://dx.doi.org/10.18632/oncotarget.21403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732742/
https://www.ncbi.nlm.nih.gov/pubmed/29262576
http://dx.doi.org/10.18632/oncotarget.21403

Ejemplares similares